KRMD Repro Med Systems Inc
Price (delayed)
$2.4
Market cap
$110.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.25
Enterprise value
$103.56M
Repro Med Systems, Inc. dba KORU Medical System develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM
Highlights
The gross profit is up by 17% year-on-year and by 9% since the previous quarter
The gross margin has grown by 12% YoY and by 3.8% from the previous quarter
KRMD's EPS is down by 47% year-on-year but it is up by 11% since the previous quarter
The net income has declined by 45% year-on-year but it has increased by 11% since the previous quarter
The company's equity fell by 33% YoY and by 2.2% QoQ
The quick ratio has contracted by 22% YoY
Key stats
What are the main financial stats of KRMD
Market
Valuations
Earnings
Shares outstanding
45.86M
Market cap
$110.05M
Enterprise value
$103.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.87
Price to sales (P/S)
3.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
Revenue
$30.82M
EBIT
-$6.61M
EBITDA
-$5.72M
Free cash flow
-$1.08M
Per share
Balance sheet
Liquidity
EPS
-$0.25
Free cash flow per share
-$0.02
Book value per share
$0.41
Revenue per share
$0.67
TBVPS
$0.58
Total assets
$27.3M
Total liabilities
$8.6M
Debt
$3.97M
Equity
$18.7M
Working capital
$14.23M
Debt to equity
0.21
Current ratio
3.77
Quick ratio
3.17
Net debt/EBITDA
1.13
Margins
Efficiency
Dividend
EBITDA margin
-18.6%
Gross margin
62.5%
Net margin
-38.2%
Operating margin
-23.2%
Return on assets
-39.7%
Return on equity
-54.9%
Return on invested capital
-37.5%
Return on capital employed
-29.8%
Return on sales
-21.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRMD stock price
How has the Repro Med Systems stock price performed over time
Intraday
-4%
1 week
-2.83%
1 month
3.9%
1 year
-9.77%
YTD
-2.44%
QTD
-9.43%
Financial performance
How have Repro Med Systems's revenue and profit performed over time
Revenue
$30.82M
Gross profit
$19.26M
Operating income
-$7.14M
Net income
-$11.76M
Gross margin
62.5%
Net margin
-38.2%
The net income has declined by 45% year-on-year but it has increased by 11% since the previous quarter
KRMD's net margin is down by 38% year-on-year but it is up by 15% since the previous quarter
The company's operating margin rose by 34% YoY and by 26% QoQ
KRMD's operating income is up by 31% YoY and by 22% from the previous quarter
Growth
What is Repro Med Systems's growth rate over time
Valuation
What is Repro Med Systems stock price valuation
P/E
N/A
P/B
5.87
P/S
3.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
KRMD's EPS is down by 47% year-on-year but it is up by 11% since the previous quarter
The company's equity fell by 33% YoY and by 2.2% QoQ
KRMD's price to book (P/B) is 19% lower than its 5-year quarterly average of 7.6 but 11% higher than its last 4 quarters average of 5.5
The P/S is 48% below the 5-year quarterly average of 7.1 and 7% below the last 4 quarters average of 4.0
The revenue has grown by 5% from the previous quarter and by 4.7% YoY
Efficiency
How efficient is Repro Med Systems business performance
Repro Med Systems's ROE has plunged by 106% YoY
Repro Med Systems's return on assets has shrunk by 95% YoY but it has increased by 4.8% QoQ
KRMD's return on sales is up by 37% year-on-year and by 28% since the previous quarter
KRMD's return on invested capital is up by 15% since the previous quarter and by 11% year-on-year
Dividends
What is KRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRMD.
Financial health
How did Repro Med Systems financials performed over time
The current ratio has contracted by 32% YoY and by 6% from the previous quarter
The total assets has contracted by 24% YoY
KRMD's debt is 79% smaller than its equity
The debt to equity rose by 40% YoY but it fell by 4.5% QoQ
The company's equity fell by 33% YoY and by 2.2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.